Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial

Benzinga_recent_news01-06 00:00

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) on Monday shared topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant for CAH and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601833200?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/05/Medical-Research-And-Development-Center-_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-06 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601833200","market":"hk","top_or_hot":-1,"title":"Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial","media":"Benzinga_recent_news","content":"<div>\n<p>Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) on Monday shared topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant for CAH and...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49697214/crinetics-experimental-pill-slashes-hormones-in-rare-adrenal-disease-trial\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-06 00:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/01/49697214/crinetics-experimental-pill-slashes-hormones-in-rare-adrenal-disease-trial><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) on Monday shared topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant for CAH and...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49697214/crinetics-experimental-pill-slashes-hormones-in-rare-adrenal-disease-trial\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930490.SGD","symbol_name":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/01/49697214/crinetics-experimental-pill-slashes-hormones-in-rare-adrenal-disease-trial","article_id":"2601833200","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/05/Medical-Research-And-Development-Center-_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49697214/crinetics-experimental-pill-slashes-hormones-in-rare-adrenal-disease-trial","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601833200","pubTimestamp":1767628800,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4585":"ETF&股票定投概念","CAH":"卡地纳健康","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4139":"生物科技","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4175":"保健护理产品经销商","CRNX":"Crinetics Pharmaceuticals Inc.","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","CORT":"Corcept医疗","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0566484027.USD":"安本美国小盘成长股","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","NBIX":"神经分泌生物科学","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4532":"文艺复兴科技持仓","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC"},"translate_title":"Crinetics实验药丸在罕见肾上腺疾病试验中削减激素","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAH":1,"NBIX":1,"CRNX":1,"CORT":1},"content_text":"Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) on Monday shared topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant for CAH and adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome.\nCAH is a genetic disease that affects the adrenal glands and prevents the production of hormones like cortisol, aldosterone, and androgens.\nTreatment with atumelnant resulted in rapid, sustained lowering of androstenedione (in all eight patients that completed the fourth cohort). Seven out of these eight patients continued to maintain lower serum androstenedione (A4) levels after glucocorticoid doses were reduced to physiologic levels.\nAlso Read: Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly\nAt an 80 mg dose, atumelnant achieved a 67% mean reduction in A4 levels while simultaneously enabling 88% of participants completing 12 weeks of treatment to reduce GC dose to physiologic replacement levels.\nAtumelnant was observed to be well-tolerated, with no serious adverse events and no treatment-related severe adverse events.\nNo participants discontinued due to adverse events. No patients experienced hepatic transaminase adverse events.\nA data snapshot with limited source data verification from the first seven patients in the Open-Label Extension (OLE) to have completed 13 weeks shows both serum A4 reductions and Glucocorticoid (GC) dose reductions that are in line with those seen in Cohort 4.\nAdditionally, investigators have not observed any serious adverse events or any treatment-related severe adverse events, and have not observed any hepatic transaminase adverse events to date, with 25 patients enrolled and with 7 participants who have completed over 20 weeks of treatment in the study.\nAtumelnant continues to be well-tolerated with a growing safety database including over 750 weeks of cumulative adult CAH patient exposure.\nIn September 2025, the U.S. Food and Drug Administration (FDA) approved the company’s Palsonify (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.\nCrinetics recognized over $5 million of revenue from Palsonify during the fourth quarter of 2025.\nIn December 2025, the FDA rejected Corcept Therapeutics Incorporated’s (NASDAQ:CORT) New Drug Application (NDA) for relacorilant for hypertension secondary to hypercortisolism.\nThe FDA concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.\nIn December 2024, the FDA approved Neurocrine Biosciences, Inc.(NASDAQ:NBIX) Crenessity (crinecerfont) as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic CAH.\nCRNX Price Action: Crinetics Pharmaceuticals shares were up 13.19% at $52.89 at the time of publication on Monday. The stock is trading near its 52-week high of $53.55, according to Benzinga Pro data.\nRead Next:\nPhoto by Gorodenkoff via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601833200","isCrawlerRequest":true}